View a panel discussion between a well-respected hematologist-oncologist, nurse practitioner, and patient caregiver advocate on the topic of myelodysplastic syndromes (MDS) treatment at home—including the advantages and disadvantages of current treatment options, patient care, and INQOVI.
*Especially in the case of transplant-ineligible patients.
†Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database between 2010 and 2016.
References: 1. Steensma DP, Komrokji RS, Stone RM, et al. Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer. 2014;120(11):1670‑1676. 2. Bell JA, Galaznik A, Blazer M, et al. Economic burden of patients treated for higher‑risk myelodysplastic syndromes (HR‑MDS) in routine clinical care in the United States. PharmacoEconomics Open. 2019;3(2): 237‑245. 3. Savona MR, Odenike O, Amrein PC, et al. An oral fixed‑dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open‑label, dose‑escalation, phase 1 study. Lancet Haematol. 2019;6(4): e194‑e203. doi:10.1016/S2352‑3026(19)30030‑4 4. Vidaza [package insert]. Summit, NJ: Celgene Corporation; 2020. 5. Leveque D. Subcutaneous administration of anticancer agents. Anticancer Research. 2014;34(4):1579‑1586. 6. Joshi N, Kale H, Corman S, et al. Direct medical costs associated with treatment nonpersistence in patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents: A large retrospective cohort analysis. Clin Lymphoma Myeloma Leuk. 2021;21(3):e248-e254. 7. Kini V, Ho PM. Interventions to improve medication adherence: A review. JAMA. 2018 Dec 18;320(23):2461-2473. 8. Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096‑1107. 9. INQOVI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2022